John Brady Ridgway

6.0k total citations · 3 hit papers
18 papers, 3.6k citations indexed

About

John Brady Ridgway is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, John Brady Ridgway has authored 18 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Oncology. Recurrent topics in John Brady Ridgway's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Glycosylation and Glycoproteins Research (5 papers) and Angiogenesis and VEGF in Cancer (4 papers). John Brady Ridgway is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Glycosylation and Glycoproteins Research (5 papers) and Angiogenesis and VEGF in Cancer (4 papers). John Brady Ridgway collaborates with scholars based in United States, Slovakia and Italy. John Brady Ridgway's co-authors include Paul Carter, Leonard G. Presta, C Gorman, Dennis J. Henner, H. Michael Shepard, Claire E. Kotts, Minhong Yan, Gu Zhang, James A. Wells and S. Atwell and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

John Brady Ridgway

18 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 1.5k citations Paul Carter, Leonard G. Presta et al. Proceedings of the National Academy of Sciences profile →
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

2006 765 citations John Brady Ridgway, Gu Zhang et al. Nature profile →
‘Knobs-into-holes’ engineering of antibody C_H3 domains for heavy chain heterodimerization

1996 564 citations John Brady Ridgway, Leonard G. Presta et al. Protein Engineering Design and Selection profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Brady Ridgway United States	14	2.2k	1.8k	1.5k	556	297	18	3.6k
Teemu T. Junttila Finland	24	1.6k 0.7×	1.6k 0.9×	2.4k 1.6×	441 0.8×	277 0.9×	32	3.7k
Sarajane Ross United States	23	2.0k 0.9×	883 0.5×	1.2k 0.8×	490 0.9×	327 1.1×	37	3.1k
Kin-Ming Lo United States	27	1.8k 0.8×	789 0.4×	1.4k 0.9×	1.1k 1.9×	688 2.3×	43	3.5k
Oreste Segatto United States	31	1.9k 0.9×	1.2k 0.6×	2.0k 1.3×	425 0.8×	357 1.2×	55	3.4k
Silvia Miotti Italy	30	1.1k 0.5×	599 0.3×	824 0.5×	685 1.2×	242 0.8×	59	2.4k
Charles N. Pegram United States	27	855 0.4×	904 0.5×	830 0.5×	521 0.9×	199 0.7×	46	2.3k
Tomoyuki Kawamoto Japan	19	1.5k 0.7×	1.0k 0.5×	1.7k 1.1×	238 0.4×	267 0.9×	26	3.0k
Ben K. Seon United States	27	1.5k 0.7×	529 0.3×	683 0.4×	642 1.2×	443 1.5×	100	2.6k
Elicia Penuel United States	22	1.1k 0.5×	698 0.4×	2.0k 1.3×	367 0.7×	274 0.9×	64	3.0k
David Flowers United States	20	1.7k 0.8×	647 0.4×	933 0.6×	524 0.9×	105 0.4×	43	3.2k

Countries citing papers authored by John Brady Ridgway

Since Specialization

Citations

This map shows the geographic impact of John Brady Ridgway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Brady Ridgway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Brady Ridgway more than expected).

Fields of papers citing papers by John Brady Ridgway

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Brady Ridgway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Brady Ridgway. The network helps show where John Brady Ridgway may publish in the future.

Co-authorship network of co-authors of John Brady Ridgway

This figure shows the co-authorship network connecting the top 25 collaborators of John Brady Ridgway. A scholar is included among the top collaborators of John Brady Ridgway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Brady Ridgway. John Brady Ridgway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Thackaberry, Evan A., Yi Zhou, Christina L. Zuch de Zafra, et al.. (2019). Rapid Development of Glaucoma Via ITV Nonselective ANGPT 1/2 Antibody: A Potential Role for ANGPT/TIE2 Signaling in Primate Aqueous Humor Outflow. Investigative Ophthalmology & Visual Science. 60(13). 4097–4097. 11 indexed citations

Couch, Jessica A., Gu Zhang, Joseph C. Beyer, et al.. (2015). Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation. Clinical Cancer Research. 22(6). 1469–1479. 20 indexed citations

Chen, Hao, John Brady Ridgway, Tao Sai, et al.. (2013). Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development. Proceedings of the National Academy of Sciences. 110(29). 11887–11892. 100 indexed citations

Niessen, Kyle, Gu Zhang, John Brady Ridgway, et al.. (2011). The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. Blood. 118(7). 1989–1997. 77 indexed citations

Niessen, Kyle, Gu Zhang, John Brady Ridgway, Hao Chen, & Minhong Yan. (2009). ALK1 signaling regulates early postnatal lymphatic vessel development. Blood. 115(8). 1654–1661. 74 indexed citations

Yan, Minhong, John Brady Ridgway, Gu Zhang, et al.. (2007). Blocking of DLL4/Notch signaling deregulates tumor angiogenesis. Cancer Research. 67. 1621–1621. 1 indexed citations

Kirchhofer, Daniel, Michael T. Lipari, Lydia Santell, et al.. (2007). Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proceedings of the National Academy of Sciences. 104(13). 5306–5311. 41 indexed citations

Ridgway, John Brady, Gu Zhang, Yan Wu, et al.. (2006). Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 444(7122). 1083–1087. 765 indexed citations breakdown →

Ridgway, John Brady, Jeffrey A. Kern, James Lee, et al.. (1999). Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines.. PubMed. 59(11). 2718–23. 61 indexed citations

10.

Atwell, S., John Brady Ridgway, James A. Wells, & Paul Carter. (1997). Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. Journal of Molecular Biology. 270(1). 26–35. 199 indexed citations

11.

Ridgway, John Brady, et al.. (1996). ‘Knobs-into-holes’ provides a rational design strategy for engineering antibody CH3 domains for heavy chain heterodimerization. Immunotechnology. 2(1). 73–73. 6 indexed citations

12.

Ridgway, John Brady, Leonard G. Presta, & Paul Carter. (1996). ‘Knobs-into-holes’ engineering of antibody C_H3 domains for heavy chain heterodimerization. Protein Engineering Design and Selection. 9(7). 617–621. 564 indexed citations breakdown →

13.

Carter, Paul, John Brady Ridgway, & Zhenping Zhu. (1995). Toward the Production of Bispecific Antibody Fragments for Clinical Applications. Journal of Hematotherapy. 4(5). 463–470. 44 indexed citations

14.

Zapata, Gerardo, John Brady Ridgway, Joyce Mordenti, et al.. (1995). Engineering linear F(ab')₂ fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Engineering Design and Selection. 8(10). 1057–1062. 12 indexed citations

15.

Saban, R., Mary Haak‐Frendscho, John Brady Ridgway, et al.. (1994). Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. Journal of Allergy and Clinical Immunology. 94(5). 836–843. 51 indexed citations

16.

Haak‐Frendscho, Mary, et al.. (1993). Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo.. The Journal of Immunology. 151(1). 351–358. 33 indexed citations

17.

Carter, Paul, Leonard G. Presta, C Gorman, et al.. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy.. Proceedings of the National Academy of Sciences. 89(10). 4285–4289. 1483 indexed citations breakdown →

18.

Miller, Harvey I., et al.. (1989). Cloning and Expression of a Yeast Ubiquitin-Protein Cleaving Activity in Escherichia Coli. Nature Biotechnology. 7(7). 698–704. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact